Lupera H, Theodore C, Ghosn M, Court B H, Wibault P, Droz J P
Department of Medicine, Institut Gustave Roussy, Villejuif, France.
Urology. 1989 Nov;34(5):281-3. doi: 10.1016/0090-4295(89)90326-9.
Eighteen patients with advanced renal cell cancer were evaluated for objective response to a combination chemotherapy regimen twenty-eight-day (d) cycles, with dacarbazine (200 mg/sq m/d, d1,2,3); cyclophosphamide (400 mg/sq m/d, d1); cisplatin (100 mg/sq m/d, d1); doxorubicin (50 mg/sq m/d, d1); vindesine (1.5 mg/sq m/d, d1,2) (DECAV). One response in 16 patients was observed (6.25%; 95% confidence limits are 0-30%). No major toxicity occurred. An important point is that the only complete remission was observed in a patient with sarcomatoid cell renal cancer. At this dose with this schedule this combination regimen appears to have no activity in renal cell carcinoma.
对18例晚期肾细胞癌患者评估了一种联合化疗方案的客观缓解情况，该方案采用28天周期，包括达卡巴嗪（200mg/平方米/天，第1、2、3天）；环磷酰胺（400mg/平方米/天，第1天）；顺铂（100mg/平方米/天，第1天）；阿霉素（50mg/平方米/天，第1天）；长春地辛（1.5mg/平方米/天，第1、2天）（DECAV）。观察到16例患者中有1例缓解（6.25%；95%置信区间为0 - 30%）。未发生严重毒性反应。一个重要的情况是，唯一的完全缓解出现在一名肉瘤样细胞肾癌症患者中。在此剂量和方案下，这种联合方案在肾细胞癌中似乎无活性。
